keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant breast cancer therapy

keyword
https://www.readbyqxmd.com/read/29782362/breast-conservation-therapy-after-neoadjuvant-chemotherapy-does-not-compromise-10-year-breast-cancer-specific-mortality
#1
Renee L Arlow, Lisa E Paddock, Xiaoling Niu, Laurie Kirstein, Bruce G Haffty, Sharad Goyal, Thomas Kearney, Deborah Toppmeyer, Antoinette M Stroup, Atif J Khan
OBJECTIVES: Neoadjuvant chemotherapy can increase the rate of breast-conserving surgery by downstaging disease in patients with breast cancer. The aim of this study was to determine whether patients who received neoadjuvant chemotherapy have equal survival after breast-conservation therapy compared with mastectomy. MATERIAL AND METHODS: Using the New Jersey State Cancer Registry (NJSCR) patients with a primary breast cancer diagnosed between 1998 and 2003 who underwent neoadjuvant chemotherapy were selected (n=1,468)...
May 18, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29772459/tyrosine-kinase-inhibitors-for-brain-metastases-in-her2-positive-breast-cancer
#2
REVIEW
Renata Duchnowska, Sibylle Loibl, Jacek Jassem
Approximately 30-50% of advanced HER2-positive breast cancer patients will develop central nervous system (CNS) metastases, with an annual risk of around 10%, and a half of them will die from brain progression. An increased risk of brain metastases is also seen in patients with early HER2-positive breast cancer administered curative therapy. Brain metastases in HER2-positive breast cancer patients usually constitute the first site of recurrence. The administration of anti-HER2 monoclonal antibodies, trastuzumab and pertuzumab, considerably delays the onset of symptomatic brain disease: however, the limited penetration of these compounds into the CNS hinders their efficacy...
May 9, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29770955/laptm4b-gene-copy-number-gain-is-associated-with-inferior-response-to-anthracycline-based-chemotherapy-in-hormone-receptor-negative-breast-carcinomas
#3
Orsolya Rusz, Orsolya Papp, Laura Vízkeleti, Béla Ákos Molnár, Kristóf Csaba Bende, Gábor Lotz, Balázs Ács, Zsuzsanna Kahán, Tamás Székely, Ágnes Báthori, Csilla Szundi, Janina Kulka, Zoltán Szállási, Anna-Mária Tőkés
PURPOSE: To determine the associations between lysosomal-associated transmembrane protein 4b (LAPTM4B) gene copy number and response to different chemotherapy regimens in hormone receptor negative (HR-) primary breast carcinomas. PATIENTS AND METHODS: Two cohorts were analyzed: (1) 69 core biopsies from HR-breast carcinomas treated with neoadjuvant chemotherapy (anthracycline based in 72.5% of patients and non-anthracycline based in 27.5% of patients). (2) Tissue microarray (TMA) of 74 HR-breast carcinomas treated with adjuvant therapy (77...
May 16, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29770779/effect-of-neoadjuvant-chemotherapy-on-the-expression-of-hormone-receptors-and-ki-67-in-chinese-breast-cancer-patients-a-retrospective-study-of-525-patients
#4
Yu-Tuan Wu, Xin Li, Lin-Jie Lu, Lu Gan, Wei Dai, Yan-Ling Shi, Vishnu Prasad Adhikari, Kai-Nan Wu, Ling-Quan Kong
This study was designed to investigate the effect of neoadjuvant chemotherapy on the expression of hormone receptors and ki67 in Chinese female breast cancer patients. The expression of estrogen receptor (ER), progesterone receptor (PR) and Ki67 among 525 neoadjuvant chemotherapy cases was studied by immunohistochemistry (IHC). Differences between specimens made through preoperative core needle biopsy (CB) and excised tissue biopsy (EB) were observed. The positive rates of ER, PR and Ki67 in CB and EB were 65...
November 1, 2017: Journal of Biomedical Research
https://www.readbyqxmd.com/read/29768500/clinically-relevant-inflammatory-breast-cancer-patient-derived-xenograft-derived-ex-vivo-model-for-evaluation-of-tumor-specific-therapies
#5
Bedrich L Eckhardt, Maria Gagliardi, LaKesla Iles, Kurt Evans, Cristina Ivan, Xiuping Liu, Chang-Gong Liu, Glauco Souza, Arvind Rao, Funda Meric-Bernstam, Naoto T Ueno, Geoffrey A Bartholomeusz
Inflammatory breast cancer (IBC) is a rare and aggressive presentation of invasive breast cancer with a 62% to 68% 5-year survival rate. It is the most lethal form of breast cancer, and early recognition and treatment is important for patient survival. Like non-inflammatory breast cancer, IBC comprises multiple subtypes, with the triple-negative subtype being overrepresented. Although the current multimodality treatment regime of anthracycline- and taxane-based neoadjuvant therapy, surgery, and radiotherapy has improved the outcome of patients with triple-negative IBC, overall survival continues to be worse than in patients with non-inflammatory locally advanced breast cancer...
2018: PloS One
https://www.readbyqxmd.com/read/29766686/multimodal-approach-in-assessment-of-the-response-of-breast-cancer-to-neoadjuvant-chemotherapy
#6
Mikhail Viktorovich Pavlov, Tatyana Igorevna Kalganova, Yekaterina Sergeevna Lyubimtseva, Vladimir Ivanovich Plekhanov, German Yurievich Golubyatnikov, Olga Yevgenyevna Ilyinskaya, Anna Gennadjevna Orlova, Pavel Vladimirovich Subochev, Dmitriy Vladimirovich Safonov, Natalia Mikhailovna Shakhova, Anna Vladimirovna Maslennikova
The ability for noninvasive visualization of functional changes of a tumor's oxygenation and circulatory system offers new advantages for prognosis and monitoring of the treatment efficacy. The results of breast cancer oxygen state study under chemotherapy action obtained by diffuse optical spectroscopy (DOS) in combination with Doppler ultrasonic imaging are presented. Complex use of optical and ultrasound methods gives complementary information about the size of the tumor node, peculiarities of its vascular bed, rate of its blood flow as well as oxygenation, and provide a picture of the tumor response to treatment...
May 2018: Journal of Biomedical Optics
https://www.readbyqxmd.com/read/29766409/where-youth-matters-clinicopathologic-characteristics-and-emerging-trends-in-treatment-and-outcomes-in-young-irish-women-with-breast-cancer
#7
Megan Greally, Jennifer Kielty, Geoffrey A Watson, Geoffrey Das, Christina Malouf, Lynda McSorley, Niamh Coleman, Cecily Quinn, Enda W McDermott, Giuseppe Gullo, John Crown, Ruth S Prichard, Catherine M Kelly, Janice M Walshe
BACKGROUND: Young women with breast cancer (YWBC) represent 7-12% of breast cancer diagnoses and ostensibly have more biologically aggressive subtypes with higher relapse and mortality rates. We studied the clinical and pathological characteristics in YWBC and examined how outcomes and treatment have evolved. METHODS: YWBC were identified from pathology databases at two tertiary centers. Patients were divided into two cohorts: those diagnosed from 2000 to 2005 (C1) and from 2006 to 2015 (C2)...
May 15, 2018: Irish Journal of Medical Science
https://www.readbyqxmd.com/read/29754997/patient-friendly-summary-of-the-acr-appropriateness-criteria-monitoring-response-to-neoadjuvant-systemic-therapy-for-breast-cancer
#8
Casey Quinlan, Jennifer W Uyeda
No abstract text is available yet for this article.
May 11, 2018: Journal of the American College of Radiology: JACR
https://www.readbyqxmd.com/read/29752333/the-endocrinology-of-male-breast-cancer
#9
REVIEW
Ian S Fentiman
Male breast cancer (MBC) is a rare disease but, as a result of epidemiological collaborations, there is now greater clarity concerning endocrine risk factors. The significant rise in global age-standardised mean BMI in men is likely to lead to increases in incidence of maturity-onset diabetes and MBC. The metabolic changes accompanying obesity decrease androgens and sex hormone-binding globulin (SHBG), thereby increasing available oestrogens. The higher rates of MBC in North and Equatorial Africa are largely due to liver damage from endemic bilharziasis and hepatitis B causing elevated oestradiol (E2 ) levels from hepatic conversion of androgen...
June 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29750305/alterations-in-mrna-profiles-of-trastuzumab%C3%A2-resistant-her%C3%A2-2%C3%A2-positive-breast-cancer
#10
Bin Zhao, Yang Zhao, Yan Sun, Haitao Niu, Long Sheng, Dongfang Huang, Li Li
Breast cancer is one of the most common malignancies in women. Neoadjuvant trastuzumab therapy improves the prognosis of certain Her‑2‑positive breast cancer patients, however around two‑thirds of patients with Her‑2‑positive breast cancer do not benefit from Her‑2‑targeted therapy. To investigate the key mechanisms in trastuzumab resistance, potential biomarkers for neoadjuvant trastuzumab sensitivity were investigated using the gene expression omnibus (GEO) database for mRNA microarray data of Her‑2‑positive breast cancer patients who received neoadjuvant trastuzumab therapy...
May 7, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29745102/serbian-consensus-of-neoadjuvant-therapy-for-breast-cancer-neopulse
#11
Lazar Popovic, Zorica Tomasevic, Ljiljana Stamatovic, Ivan Markovic, Gorana Matovina-Brko, Marko Buta, Andrija Golubovic, Vladimir Selakovic, Jasna Trifunovic, Zafir Mutrezani, Nebojsa Ivanovic, Jasmina Nedovic, Srdjan Ninkovic, Sladjana Filipovic, Ana Cvetanovic, Nebojsa Djordjevic, Aleksandar Karanikolic, Tatjana Ivkovic-Kapic, Ferenc Vicko
Even though surgery is the primary treatment of operable breast cancer, it has been known for decades that the administration of postoperative adjuvant or preoperative neoadjuvant therapy is extremely important. Indications for neodjuvant therapy administration have been expanded over the years, and nowadays this kind of treatment represents an inevitable option in early breast cancer treatment. The NeoPULSE project, which gathered a group of experts in the field of breast cancer from five Serbian university centres, was formed with the aim to define optimal breast cancer diagnosis, indications for neoadjuvant therapy, therapeutic combinations in relation to molecular/biological parameters of breast cancer, as well as the treatment after neoadjuvant therapy...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29744672/efficacy-and-safety-of-neoadjuvant-treatment-with-bevacizumab-liposomal-doxorubicin-cyclophosphamide-and-paclitaxel-combination-in-locally-regionally-advanced-her2-negative-grade-iii-at-premenopausal-status-breast-cancer-a-phase-ii-study
#12
Ekaterini C Tampaki, Athanasios Tampakis, Constantinos E Alifieris, Dimitrios Krikelis, Anastasia Pazaiti, Michalis Kontos, Dimitrios T Trafalis
BACKGROUND: In the era of personalized therapy, targeted treatment in specific patient populations is mandated. OBJECTIVE: We evaluated the efficacy and safety of neoadjuvant treatment on locally advanced breast cancer (LABC) with a monoclonal agent against vascular endothelial growth factor (VEGF), bevacizumab plus chemotherapy combination of liposomal doxorubicin, cyclophosphamide and paclitaxel (PLAC-B). METHODS: Patients enrolled were at premenopausal status and characterized by human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor positive (estrogen receptor/progesterone receptor-positive [ER/PR+]) or triple-negative (TNBC), LABC (T > 3 cm), with high-grade ductal carcinoma...
May 9, 2018: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29742918/can-unenhanced-mri-of-the-breast-replace-contrast-enhanced-mri-in-assessing-response-to-neoadjuvant-chemotherapy
#13
Beatrice Cavallo Marincola, Marianna Telesca, Fulvio Zaccagna, Frank Riemer, Michele Anzidei, Carlo Catalano, Federica Pediconi
Background The goals of neoadjuvant chemotherapy (NAC) are to reduce tumor volume and to offer a prognostic indicator in assessing treatment response. Contrast-enhanced magnetic resonance imaging (CE-MRI) is an established method for evaluating response to NAC in patients with breast cancer. Purpose To validate the role of unenhanced MRI (ue-MRI) compared to CE-MRI for assessing response to NAC in women with breast cancer. Material and Methods Seventy-one patients with ongoing NAC for breast cancer underwent MRI before, during, and at the end of NAC...
January 1, 2018: Acta Radiologica
https://www.readbyqxmd.com/read/29741562/low-estrogen-receptor-er-positive-breast-cancer-and-neoadjuvant-systemic-chemotherapy-is-response-similar-to-typical-er-positive-or-er-negative-disease
#14
Alessandra Landmann, Daniel J Farrugia, Li Zhu, Emilia J Diego, Ronald R Johnson, Atilla Soran, David J Dabbs, Beth Z Clark, Shannon L Puhalla, Rachel C Jankowitz, Adam M Brufsky, Gretchen M Ahrendt, Priscilla F McAuliffe, Rohit Bhargava
Objectives: Pathologic complete response (pCR) rate after neoadjuvant chemotherapy was compared between 141 estrogen receptor (ER)-negative (43%), 41 low ER+ (13%), 47 moderate ER+ (14%), and 98 high ER+ (30%) tumors. Methods: Human epidermal growth factor receptor 2-positive cases, cases without semiquantitative ER score, and patients treated with neoadjuvant endocrine therapy alone were excluded. Results: The pCR rate of low ER+ tumors was similar to the pCR rate of ER- tumors (37% and 26% for low ER and ER- respectively, P = ...
May 8, 2018: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29739815/impact-of-hormone-receptor-status-on-the-efficacy-of-her2-targeted-treatment
#15
Bin Zhao, Hong Zhao, Jiaxin Zhao
The introduction of human epidermal growth factor receptor 2 (HER2)-targeted drugs into routine clinical practice has a dramatic effect on the outlook for patients with HER2-positive breast cancer (BC). However, the association between efficacy of HER2-targeted therapy and hormone receptor (HR) status is still unclear. Here we conducted a meta-analysis of randomized controlled trials (RCTs) to address this issue in both neoadjuvant and adjuvant settings. PubMed and EMBASE were searched from inception to October 2017 for studies involving trastuzumab, lapatinib, pertuzumab, trastuzumab emtansine and neratinib...
June 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29734046/impact-of-neoadjuvant-chemotherapy-and-pathological-complete-response-on-eligibility-for-breast-conserving-surgery-in-patients-with-early-breast-cancer-a-meta-analysis
#16
Carmen Criscitiello, Mehra Golshan, William T Barry, Giulia Viale, Stephanie Wong, Michele Santangelo, Giuseppe Curigliano
PURPOSE: We conducted a meta-analysis of randomised trials evaluating pathological complete response (pCR) and surgical outcomes after neoadjuvant systemic therapy (NST) in patients with early breast cancer (EBC). PATIENTS AND METHODS: The primary outcome was breast-conserving surgery (BCT) rate. Secondary outcomes were pCR rate and association to BCT. Meta-analyses were performed using random effects models that use inverse-variance weighting for each treatment arm based on evaluable patients...
May 4, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29733541/a-multicenter-phase-ii-trial-of-neoadjuvant-letrozole-plus-low-dose-cyclophosphamide-in-postmenopausal-patients-with-estrogen-receptor-positive-breast-cancer-jbcrg-07-therapeutic-efficacy-and-clinical-implications-of-circulating-endothelial-cells
#17
Takayuki Ueno, Norikazu Masuda, Shunji Kamigaki, Takashi Morimoto, Futoshi Akiyama, Masafumi Kurosumi, Hitoshi Tsuda, Yoshiki Mikami, Sunao Tanaka, Satoshi Morita, Masakazu Toi
Neoadjuvant endocrine therapy has been reported to decrease tumor size, which leads to increased breast conservation rates. To improve the clinical response, metronomic chemotherapy with endocrine therapy is a promising strategy. A multicenter phase II single-arm neoadjuvant trial with letrozole and cyclophosphamide was conducted. Eligibility criteria included postmenopausal status, T2-4 N0-1, and estrogen receptor-positive breast carcinoma. Letrozole (2.5 mg) plus cyclophosphamide (50 mg) was given orally once a day for 24 weeks...
May 7, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29723396/risk-factors-for-locoregional-disease-recurrence-after-breast-conserving-therapy-in-patients-with-breast-cancer-treated-with-neoadjuvant-chemotherapy-an-international-collaboration-and-individual-patient-meta-analysis
#18
Antonios Valachis, Eleftherios P Mamounas, Elizabeth A Mittendorf, Naoki Hayashi, Makoto Ishitobi, Clara Natoli, Florian Fitzal, Isabel T Rubio, Daniel G Tiezzi, Hee-Chul Shin, Stewart J Anderson, Kelly K Hunt, Naoko Matsuda, Shozo Ohsumi, Athina Totomi, Cecilia Nilsson
BACKGROUND: Several studies have reported a high risk of local disease recurrence (LR) and locoregional disease recurrence (LRR) in patients with breast cancer after neoadjuvant chemotherapy (NCT) and breast-conserving therapy (BCT). The objective of the current study was to identify potential risk factors for LR and LRR after NCT and BCT. METHODS: Individual patient data sets from 9 studies were pooled. The outcomes of interest were the occurrence of LR and/or LRR...
May 3, 2018: Cancer
https://www.readbyqxmd.com/read/29721054/international-consensus-on-the-clinical-management-of-inflammatory-breast-cancer-from-the-morgan-welch-inflammatory-breast-cancer-research-program-10th-anniversary-conference
#19
Naoto T Ueno, Jose Rodrigo Espinosa Fernandez, Massimo Cristofanilli, Beth Overmoyer, Dan Rea, Fedor Berdichevski, Mohamad El-Shinawi, Jennifer Bellon, Huong T Le-Petross, Anthony Lucci, Gildy Babiera, Sarah M DeSnyder, Mediget Teshome, Edward Chang, Bora Lim, Savitri Krishnamurthy, Michael C Stauder, Simrit Parmar, Mona M Mohamed, Angela Alexander, Vicente Valero, Wendy A Woodward
National and international experts in inflammatory breast cancer (IBC) from high-volume centers treating IBC recently convened at the 10th Anniversary Conference of the Morgan Welch Inflammatory Breast Cancer Research Program at The University of Texas MD Anderson Cancer Center in Houston Texas. A consensus on the clinical management of patients with IBC was discussed, summarized, and subsequently reviewed. All participants at the conference (patients, advocates, researchers, trainees, and clinicians) were queried using the MDRing electronic survey on key management issues...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29719582/platinum-based-neoadjuvant-chemotherapy-in-brca1-positive-breast-cancer-a-retrospective-cohort-analysis-and-literature-review
#20
Nikolai Havn Sæther, Elina Skuja, Arvids Irmejs, Jelena Maksimenko, Edvins Miklasevics, Gunta Purkalne, Janis Gardovskis
Background: There is increasing evidence of high platinum sensitivity in BRCA -associated breast cancer. However, evidence from randomized trials is lacking. The aim of this study was to analyze the results of platinum-based chemotherapy for BRCA1-positive breast cancer in a neoadjuvant setting. Methods: A retrospective study was performed by obtaining information from patient files. The results were compared with the available data from a literature review. Results: Twelve female patients with BRCA1 gene mutations who had stage I to III breast cancers were eligible for evaluation...
2018: Hereditary Cancer in Clinical Practice
keyword
keyword
74676
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"